Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877516 | 0.86 | TSHR (0.63) | BCHEACHEEGFRTSHRMEN1 | |
| SCHEMBL6335583 | 0.84 | MAOB (0.60) | BCHEACHETSHRNPC1LMNA | |
| SCHEMBL4987644 | 0.81 | PLA2G4B (0.63) | GSK3BPTPN1NPC1MEN1KMT2A | |
| SCHEMBL4983185 | 0.80 | PLA2G4B (0.65) | GSK3BPTPN1NPC1MEN1KMT2A | |
| SCHEMBL1122947 | 0.78 | LPAR1 (0.59) | PKM | |
| SCHEMBL14087168 | 0.77 | ACHE (0.52) | BCHEACHEGSK3BPTPN1EGFR | |
| SCHEMBL41220 | 0.77 | NR4A1 (0.70) | GSK3BPTPN1EGFRLMNACYP1A2 | |
| SCHEMBL1122800 | 0.77 | MAPT (0.62) | NPC1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1122672 | 0.76 | PKM (0.63) | BCHEACHEEGFRMEN1KMT2A | |
| SCHEMBL631740 | 0.76 | THRA (0.57) | BCHEACHEGSK3BEGFRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-6864268-B2 | β3 adrenergic receptor agonists | PFIZER INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1485379-A1 | BETA 3-ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| US-6706743-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC | 2004-03-16 | — | — | US | disclosed |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| WO-2003072572-A1 | BETA3-ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1326861-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6566377-B2 | β3 adrenergic receptor agonists and uses thereof | PFIZER INC. | 2003-05-20 | — | — | US | disclosed |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | DAY ROBERT F (US) | 2002-05-02 | — | — | US | disclosed |
| WO-2002032897-A1 | ALPHA-ARYL ETHANOLAMINES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203913-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | BCHE 2555/4885ACHE 2125/4885GSK3B 588/4885 |
| US-20030212063-A1 | beta3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | BCHE 1604/4885ACHE 1183/4885GSK3B 782/4885 |
| US-20050075323-A1 | Beta3 adrenergic receptor agonists and uses thereof | ADRB3, ADRB1, ADRB2 | BCHE 2366/4885ACHE 1517/4885GSK3B 465/4885 |
| US-20020052392-A1 | Bita3 adrenergic receptor agonists and uses thereof | ADRB3, ADRA1A, ADRB1 | BCHE 1740/4885ACHE 3710/4885GSK3B 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.